SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease

被引:135
作者
Wang, WY
Shi, LY
Xie, YB
Ma, C
Li, WM
Su, XW
Huang, SJ
Chen, RH
Zhu, ZY
Mao, ZX
Han, YF
Li, MT
机构
[1] Sun Yat Sen Univ, Zhongshan Med Coll, Dept Pharmacol, Guangzhou 510089, Peoples R China
[2] Sun Yat Sen Univ, Zhongshan Med Coll, Proteom Lab, Guangzhou 510089, Peoples R China
[3] Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China
[4] Brown Univ, Rhode Isl Hosp, Sch Med, Liver Res Ctr, Providence, RI 02903 USA
[5] Brown Univ, Sch Med, Dept Med, Providence, RI 02903 USA
基金
中国国家自然科学基金;
关键词
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; SP600125; C-jun N-terminal kinase; phospho-C-jun; dopaminergic neurons; Parkinson; mouse;
D O I
10.1016/j.neures.2003.10.012
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Increasing evidence suggests that c-Jun N-terminal kinase (INK) is an important kinase mediating neuronal apoptosis in Parkinson's disease (PD) model induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). In order to study roles of JNK activity in neuronal apoptosis in this model, we blocked JNK activity in vivo using a specific inhibitor of JNK, SP600125. Our data showed that MPTP-induced phospho-c-Jun of substantial nigral neurons, caused apoptosis of dopaminergic neurons, and decreased the dopamine level in striatal area. We found that inhibiting JNK with SP600125 reduced the levels of c-Jun phosphorylation, protected dopaminergic neurons from apoptosis, and partly restored the level of dopamine in MPTP-induced PD in C57BL/6N mice. These results indicate that INK pathway is the major mediator of the neurotoxic effects of MPTP in vivo and inhibiting JNK activity may represent a new and effective strategy to treat PD. (C) 2003 Elsevier Ireland Ltd and The Japan Neuroscience Society. All rights reserved.
引用
收藏
页码:195 / 202
页数:8
相关论文
共 45 条
[1]   Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [J].
Ara, J ;
Przedborski, S ;
Naini, AB ;
Jackson-Lewis, V ;
Trifiletti, RR ;
Horwitz, J ;
Ischiropoulos, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (13) :7659-7663
[2]   EVALUATION OF A 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP)-TREATED C57 BLACK MOUSE MODEL FOR PARKINSONISM [J].
ARAI, N ;
MISUGI, K ;
GOSHIMA, Y ;
MISU, Y .
BRAIN RESEARCH, 1990, 515 (1-2) :57-63
[3]  
BAKKENBERG B, 1991, J NEUROL NEUROSUR PS, V54, P30
[4]   SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase [J].
Bennett, BL ;
Sasaki, DT ;
Murray, BW ;
O'Leary, EC ;
Sakata, ST ;
Xu, WM ;
Leisten, JC ;
Motiwala, A ;
Pierce, S ;
Satoh, Y ;
Bhagwat, SS ;
Manning, AM ;
Anderson, DW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (24) :13681-13686
[5]   Chronic exposure to MPTP as a primate model of progressive parkinsonism: A pilot study with a free radical scavenger [J].
Blanchet, PJ ;
Konitsiotis, S ;
Hyland, K ;
Arnold, LA ;
Pettigrew, KD ;
Chase, TN .
EXPERIMENTAL NEUROLOGY, 1998, 153 (02) :214-222
[6]   Signal transduction by the JNK group of MAP kinases [J].
Davis, RJ .
CELL, 2000, 103 (02) :239-252
[7]   JNK1 - A PROTEIN-KINASE STIMULATED BY UV-LIGHT AND HA-RAS THAT BINDS AND PHOSPHORYLATES THE C-JUN ACTIVATION DOMAIN [J].
DERIJARD, B ;
HIBI, M ;
WU, IH ;
BARRETT, T ;
SU, B ;
DENG, TL ;
KARIN, M ;
DAVIS, RJ .
CELL, 1994, 76 (06) :1025-1037
[8]  
Eberhardt O, 2000, J NEUROSCI, V20, P9126
[9]  
Fall CP, 1999, J NEUROSCI RES, V55, P620, DOI 10.1002/(SICI)1097-4547(19990301)55:5<620::AID-JNR9>3.0.CO
[10]  
2-S